Literature DB >> 24549481

[Systemic therapy with anti-infective agents. Principles of rational use of systemic antibiotics in dermatology].

C Sunderkötter1, R Brehler, K Becker.   

Abstract

BACKGROUND: Antibiotics are frequently prescribed and extremely valuable drugs, because they are curative. However, their often incorrect use is the main reason for the increase of multiresistant pathogens. Inappropriate prescription of broad spectrum antibiotics for skin and soft tissue infections favors the selection and spread of multiresistant bacteria not only in the skin, but also in remote visceral organs (e.g. in the intestines), due to their systemic distribution and effects in the body (so-called collateral damage). For this reason basic knowledge and special prudence when using antibiotics are just as desirable as an awareness of responsibility for the public welfare. AIM: This article intends to convey basic knowledge on the indications and selection of suitable antibiotics as well as on the development of bacterial resistance and it gives recommendations for allergological procedures when patients report alleged drug reactions to antibiotics.
RESULTS: Systemic antibiotics for soft tissue infections are indicated when the infection spreads within the tissue so that it is no longer accessible for local antiseptics. In addition to the clinical symptoms, important parameters are high blood sedimentation rates (BSR) and high levels of C-reactive protein (CRP), leukocytosis with neutrophilia and fever (not always present in elderly or immunosuppressed patients). Certain constellations, such as the presence of severe underlying diseases, perfusion disorders or a particular localization (e.g. infection of the face) may necessitate early or parenteral administration. There is no need for systemic administration of antibiotics for uncomplicated wounds without soft tissue infections. Due to their curative effects, the decisive criterion for the use of antibiotics is their sufficient antimicrobial efficacy at the site of infection. An inappropriate administration increases both the selection pressure and costs of treatment and can have fatal consequences in serious situations. In dermatological patients the beta-lactam antibiotics penicillin V, penicillin G and cephalosporins of groups 1 and 2 are the antibiotics most commonly indicated for skin and soft tissue infections. If the patient's history arouses the suspicion of incompatibility to these antibiotics, allergological diagnostics should be carried out in order to avoid as often as possible the alternative use of antibiotics which result in more undesired effects and development of resistance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24549481     DOI: 10.1007/s00105-013-2653-7

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  15 in total

Review 1.  Drug allergy.

Authors:  David A Khan; Roland Solensky
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

2.  [Skin infections with MRSA. Epidemiology and clinical features].

Authors:  K Becker; C Sunderkötter
Journal:  Hautarzt       Date:  2012-05       Impact factor: 0.751

Review 3.  Antibiotic prescribing in hospitals: a social and behavioural scientific approach.

Authors:  Marlies E J L Hulscher; Richard P T M Grol; Jos W M van der Meer
Journal:  Lancet Infect Dis       Date:  2010-03       Impact factor: 25.071

Review 4.  The use of cephalosporins in penicillin-allergic patients: a literature review.

Authors:  James D Campagna; Michael C Bond; Esteban Schabelman; Bryan D Hayes
Journal:  J Emerg Med       Date:  2011-07-13       Impact factor: 1.484

5.  Population dynamics among methicillin-resistant Staphylococcus aureus isolates in Germany during a 6-year period.

Authors:  Frieder Schaumburg; Robin Köck; Alexander Mellmann; Laura Richter; Felicitas Hasenberg; André Kriegeskorte; Alexander W Friedrich; Sören Gatermann; Georg Peters; Christof von Eiff; Karsten Becker
Journal:  J Clin Microbiol       Date:  2012-07-18       Impact factor: 5.948

6.  [Persistent and recurrent skin and soft tissue infections by Staphylococcus aureus. Impact of the small colony-variant (SCV) phenotype and of Panton-Valentine leukocidin (PVL)-positive S. aureus isolates].

Authors:  K Becker; A Kriegeskorte; C Sunderkötter; B Löffler; C von Eiff
Journal:  Hautarzt       Date:  2014-01       Impact factor: 0.751

7.  Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

Authors:  Jesús Rodríguez-Baño; Encarnación Picón; Paloma Gijón; José Ramón Hernández; Jose M Cisneros; Carmen Peña; Manuel Almela; Benito Almirante; Fabio Grill; Javier Colomina; Sonia Molinos; Antonio Oliver; Carlos Fernández-Mazarrasa; Gemma Navarro; Ana Coloma; Lorena López-Cerero; Alvaro Pascual
Journal:  J Clin Microbiol       Date:  2010-02-24       Impact factor: 5.948

8.  IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems.

Authors:  Antonino Romano; Francesco Gaeta; Rocco Luigi Valluzzi; Cristiano Caruso; Gabriele Rumi; Philippe Jean Bousquet
Journal:  J Allergy Clin Immunol       Date:  2010-11       Impact factor: 10.793

Review 9.  Update on the evaluation of hypersensitivity reactions to betalactams.

Authors:  M Blanca; A Romano; M J Torres; J Férnandez; C Mayorga; J Rodriguez; P Demoly; P J Bousquet; H F Merk; M L Sanz; H Ott; M Atanasković-Marković
Journal:  Allergy       Date:  2009-02       Impact factor: 13.146

10.  Penicillin allergy and desensitization in serious infections during pregnancy.

Authors:  G D Wendel; B J Stark; R B Jamison; R D Molina; T J Sullivan
Journal:  N Engl J Med       Date:  1985-05-09       Impact factor: 91.245

View more
  1 in total

1.  Treatment of folliculitis decalvans using intensity-modulated radiation via tomotherapy.

Authors:  Khaled Elsayad; Jan Kriz; Uwe Haverkamp; Kerasia-Maria Plachouri; Antonia Jeskowiak; Cord Sunderkötter; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2015-09-23       Impact factor: 3.621

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.